Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Therapeutics PLC

28.66
+0.59002.10%
Post-market: 28.660.00000.00%19:55 EDT
Volume:1.92M
Turnover:55.19M
Market Cap:21.28B
PE:-84.40
High:29.25
Open:28.43
Low:28.20
Close:28.07
52wk High:36.91
52wk Low:10.30
Shares:742.67M
Float Shares:116.05M
Volume Ratio:0.76
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3396
EPS(LYR):-0.3080
ROE:-123.93%
ROA:-52.50%
PB:61.82
PE(LYR):-93.05

Loading ...

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Focus on Inflation Data

MT Newswires Live
·
Feb 24

BUZZ-U.S. STOCKS ON THE MOVE-Nike, Domino's Pizza, Apple

Reuters
·
Feb 24

Summit Therapeutics Partners With Pfizer to Test Cancer Drug Combinations

MT Newswires Live
·
Feb 24

BRIEF-Summit Therapeutics Collaborates With Pfizer To Evaluate Ivonescimab Trial

Reuters
·
Feb 24

Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos

Dow Jones
·
Feb 24

BUZZ-Summit Therapeutics rises on clinical trial collaboration with Pfizer

Reuters
·
Feb 24

Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise -- Shares Up Pre-Bell

MT Newswires Live
·
Feb 24

Stock Track | Summit Therapeutics Soars 6.69% Pre-market on Clinical Trial Collaboration with Pfizer

Stock Track
·
Feb 24

Earnings Flash (SMMT) Summit Therapeutics Posts Q4 Total Operating Expenses of $65.8M

MT Newswires Live
·
Feb 24

Summit Therapeutics Q4 2024 Adj EPS $(0.07) Beats $(0.08) Estimate

Benzinga
·
Feb 24

BRIEF-Summit Therapeutics Q4 Net Income USD -61.2 Million

Reuters
·
Feb 24

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Business Wire
·
Feb 24

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Business Wire
·
Feb 24

Insider Stock Buying Reaches US$78.8m On Summit Therapeutics

Simply Wall St.
·
Feb 23

Press Release: Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Dow Jones
·
Feb 18

Summit Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Feb 14